Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: An analysis by gender and menopausal status

Osteoporosis International

Volumn 20, Issue 12, 2009, Pages 2095-2104

  Langdahl, B L ^a   Marin, F ^b   Shane, E ^c   Dobnig, H ^d   Zanchetta, J R ^e   Maricic, M ^f   Krohn, K ^b   See, K ^b   Warner, M R ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ELI LILLY AND COMPANY   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSIDAD DEL SALVADOR   (Argentina)

^f Catalina Pointe Arthritis and Rheumatology Specialists   (United States)

Author keywords

Alendronate; Bone biomarkers; Glucocorticoid induced osteoporosis; PINP; Premenopausal; Teriparatide

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; FRAGILITY FRACTURE; HIP; HUMAN; HYPERTENSION; INFLUENZA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MULTICENTER STUDY; MYALGIA; NAUSEA; OSTEOARTHRITIS; PNEUMONIA; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; VOMITING;

ADULT; AGE FACTORS; AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PREMENOPAUSE; SEX FACTORS; TERIPARATIDE; TREATMENT OUTCOME;

EID: 71849093622     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0917-y     Document Type: Article

References (43)

1. TP Van Staa HGM Leufkens L Abenhaim, et al. 2000 Use of oral corticosteroids and risk for fractures J Bone Miner Res 15 993 1000 10.1359/jbmr.2000.15.6.993 10841167 (Pubitemid 30350061)
2. KG Saag 2003 Glucocorticoid-induced osteoporosis Endocrinol Metab Clin North Am 32 135 157 10.1016/S0889-8529(02)00064-6 1:CAS:528:DC%2BD3sXjtFOjsbo%3D 12699296 (Pubitemid 36378638)
3. E Canalis G Mazziotti A Giustina, et al. 2004 Glucocorticoid-induced osteoporosis: pathophysiology and perspective Osteoporos Int 18 1319 1328 10.1007/s00198-007-0394-0
4. JA Kanis H Johansson A Oden, et al. 2004 A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 893 899 10.1359/JBMR.040134 15125788 (Pubitemid 41103445)
5. RS Weinstein RL Jilka AM Parfitt, et al. 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone J Clin Invest 102 274 282 10.1172/JCI2799 1:CAS:528:DyaK1cXkslOktrc%3D 9664068
6. MR Rubin JP Bilezikian 2002 The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a reexamination of the evidence J Clin Endocrinol Metab 87 4033 4041 10.1210/jc.2002-012101 1:CAS:528:DC%2BD38XntFOmur4%3D 12213840
7. O Schakman H Gilson JP Thissen 2008 Mechanism of glucocorticoid-induced myopathy J Endocrinol 197 1 10 10.1677/JOE-07-0606 1:CAS:528: DC%2BD1cXltlertr4%3D 18372227 (Pubitemid 351566920)
8. American College of Rheumatology 2001 Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis Arthritis Rheum 44 1496 1503 10.1002/1529-0131(200107)44:7<1496::AID- ART271>3.0.CO;2-5 (Pubitemid 32642211)
9. PN Sambrook T Diamond L Ferris, et al. 2001 Corticosteroid induced osteoporosis. Guidelines for treatment Aust Fam Physician 30 793 796 1:STN:280:DC%2BD3MrnsVSqsA%3D%3D 11681155
10. Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London, UK. http://www.rcplondon.ac.uk/ pubs/books/glucocorticoid/index.asp
11. RA Adler MC Hochberg 2003 Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs Arch Intern Med 163 2619 2624 10.1001/archinte.163.21.2619 14638562 (Pubitemid 37464420)
12. PP Geusens RN de Nijs WF Lems, et al. 2004 Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology Ann Rheum Dis 63 324 325 10.1136/ard.2003.008060 1:STN:280:DC%2BD2c7gslelsw%3D%3D 14962971 (Pubitemid 38250679)
13. H Nawata S Soen R Takayanagi, et al. 2005 Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research J Bone Miner Metab 23 105 109 10.1007/s00774-004- 0596-x 15750687 (Pubitemid 40591032)
14. JP Devogelaer S Goemaere S Boonen, et al. 2006 Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club Osteoporos Int 17 8 19 10.1007/s00198-005-2032-z 1:CAS:528:DC%2BD2MXhtlWkt7rK 16217586 (Pubitemid 41798023)
15. MJ Rogers JC Frith SP Luckman, et al. 1999 Molecular mechanisms of action of bisphosphonates Bone 24 73S 79S 10.1016/S8756-3282(99)00070-8 1:CAS:528:DyaK1MXjtVGitLc%3D 10321934 (Pubitemid 29202003)
16. H Dobnig RT Turner 1995 Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells Endocrinology 136 3632 3638 10.1210/en.136.8.3632 1:CAS:528:DyaK2MXntFKntbs%3D 7628403
17. RL Jilka RS Weinstein T Bellido, et al. 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone J Clin Invest 104 439 446 10.1172/JCI6610 1:CAS:528:DyaK1MXltlekur8%3D 10449436
18. E Canalis A Giustina JP Bilezikian 2007 Mechanisms of anabolic therapies for osteoporosis N Engl J Med 357 905 916 10.1056/NEJMra067395 1:CAS:528:DC%2BD2sXpvVylurk%3D 17761594 (Pubitemid 47347324)
19. D Goltzman 2008 Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone Arch Biochem Biophys 473 218 224 10.1016/j.abb.2008.03.003 1:CAS:528:DC%2BD1cXlsFOgtbc%3D 18358824
20. KG Saag ES Shane S Boonen, et al. 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis New Eng J Med 357 2028 2039 10.1056/NEJMoa071408 1:CAS:528:DC%2BD2sXhtlWis7rP 18003959 (Pubitemid 350106710)
21. HK Genant M Jergas L Palermo, et al. 1996 Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis J Bone Miner Res 11 984 996 1:STN:280:DyaK28zptVShtA%3D%3D 8797120
22. KG Saag R Emkey TJ Schnitzer, et al. 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis N Engl J Med 339 292 299 10.1056/NEJM199807303390502 1:CAS:528:DyaK1cXlsVOitr4%3D 9682041 (Pubitemid 28366417)
23. JD Adachi KG Saag PD Delmas, et al. 2001 Two year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double blind, placebo controlled extension trial Arthritis Rheum 44 202 211 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3. 0.CO;2-W 1:CAS:528:DC%2BD3MXht1yiu7o%3D 11212161 (Pubitemid 32113136)
24. S Cohen RM Levy M Keller, et al. 1999 Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 2309 2318 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K 1:CAS:528:DyaK1MXnvVShsLs%3D 10555025 (Pubitemid 30333410)
25. DM Reid RA Hughes RF Laan, et al. 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial J Bone Miner Res 15 1006 1013 10.1359/jbmr.2000.15.6. 1006 1:CAS:528:DC%2BD3cXktFKhtbs%3D 10841169
26. JD Ringe A Dorst H Faber, et al. 2003 Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study Osteoporos Int 14 10 801 807 10.1007/s00198-003-1425-0 1:CAS:528:DC%2BD3sXosFWrsLw%3D 14610641 (Pubitemid 37462129)
27. S Wallach S Cohen DM Reid, et al. 2000 Effects of risedronate treatment on bone density and vertebral fracture in patients on corticoid therapy Calcif Tissue Int 67 277 285 10.1007/s002230001146 1:CAS:528:DC%2BD3cXntlOlu74%3D 11000340 (Pubitemid 30736856)
28. WF Lems MC Lodder P Lips, et al. 2006 Positive effects of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial Osteoporos Int 17 716 723 10.1007/s00198-005-0037-2 1:CAS:528:DC%2BD28XjsVertro%3D 16463007
29. RN de Nijs JW Jacobs WF Lems, et al. 2006 Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis N Engl J Med 355 675 684 10.1056/NEJMoa053569 16914703 (Pubitemid 44244538)
30. PN Sambrook 2007 Anabolic therapy in glucocorticoid-induced osteoporosis N Engl J Med 357 2084 2086 10.1056/NEJMe0706770 1:CAS:528:DC%2BD2sXhtlWis7vE 18003966 (Pubitemid 350106719)
31. NE Lane S Sanchez GW Modin, et al. 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial J Clin Invest 102 1627 1633 10.1172/JCI3914 1:CAS:528: DyaK1cXmvVynsL0%3D 9788977
32. Q Rehman TF Lang CD Arnaud, et al. 2003 Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis Osteoporos Int 14 77 81 10.1007/s00198-002-1312-0 1:CAS:528:DC%2BD3sXpvFOqsQ%3D%3D 12577188 (Pubitemid 36267904)
33. P Chen PD Miller R Recker, et al. 2007 Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis J Bone Miner Res 22 1173 1180 10.1359/jbmr.070413 1:CAS:528:DC%2BD2sXptlGlsr4%3D 17451369 (Pubitemid 351339699)
34. SR Cummings DB Karpf F Harris, et al. 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289 10.1016/S0002-9343(01)01124-X 1:CAS:528:DC%2BD38XhvVWkurk%3D 11893367 (Pubitemid 34219441)
35. Z Li MP Meredith MS Hoseyni 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint Statist Med 20 3175 3188 10.1002/sim.984 1:STN:280:DC%2BD3MnpvVyktg%3D%3D (Pubitemid 33034879)
36. TM Keaveny DW Donley PF Hoffmann BH Mitlak EV Glass JA San Martin 2007 Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis J Bone Miner Res 21 149 157 10.1359/jbmr.061011 (Pubitemid 46032608)
37. R Ramsey-Goldman JE Dunn CF Huang, et al. 1999 Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data Arthritis Rheum 42 882 890 10.1002/1529-0131(199905)42:5<882: :AID-ANR6>3.0.CO;2-C 1:STN:280:DyaK1M3lsFShsA%3D%3D 10323443 (Pubitemid 29214998)
38. M Steinbuch TE Youket S Cohen 2004 Oral glucocorticoid use is associated with an increased risk of fracture Osteoporos Int 15 323 328 10.1007/s00198-003-1548-3 1:CAS:528:DC%2BD2cXis1Ghu7g%3D 14762652 (Pubitemid 38543952)
39. J Klaus G Armbrecht M Steinkamp, et al. 2002 High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease Gut 51 654 658 10.1136/gut.51.5.654 1:STN:280:DC%2BD38nitVGmtQ%3D%3D 12377802 (Pubitemid 35216851)
40. RM Neer CD Arnaud JR Zanchetta, et al. 2001 Effect of parathyroid hormone(1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 19 1434 1441 10.1056/NEJM200105103441904 1:CAS:528:DC%2BD3MXktVSgsbw%3D 11346808 (Pubitemid 32402100)
41. ES Orwoll WH Scheele S Paul, et al. 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J Bone Miner Res 18 9 17 10.1359/jbmr.2003.18.1.9 1:CAS:528:DC%2BD3sXltFKmtw%3D%3D 12510800 (Pubitemid 36008334)
42. UA Liberman SR Weiss J Bröll, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N Engl J Med 333 1437 1443 10.1056/NEJM199511303332201 1:CAS:528:DyaK28XkslehtA%3D%3D 7477143
43. AK McDonough JR Curtis KG Saag 2008 The epidemiology of glucocorticoid-associated adverse events Curr Opin Rheumatol 20 131 137 10.1097/BOR.0b013e3282f51031 18349741 (Pubitemid 351339883)